Thursday, July 9, 2026

pharma · Chronic Diabetic Foot Ulcers · Diabetic Foot Infection · LABT

Lakewood-Amedex Biotherapeutics

Lakewood-Amedex Biotherapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

University Park, USA HQ
8 Employees
Public company Type
LABT · NYSE Ticker
Company details
Status
Public
HQ
University Park, USA
Employees
8
Programs
4
Drugs
1
Patents
18
Intelligence · Clinical Programs

Lakewood-Amedex Biotherapeutics projects

4 ClinicalTrials.gov programs sponsored by Lakewood-Amedex Biotherapeutics.

Lakewood-Amedex Biotherapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 5% Bisphosphocin Topical Gel

    Lakewood-Amedex Biotherapeutics

    Chronic Diabetic Foot Ulcers

    phase 2 small molecule terminated

    1 trial
  2. 5% Nu-3 gel

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Infection

    phase 2 small molecule active

    1 trial
  3. Antimicrobial agent

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Ulcers (DFUs)

    phase 2 small molecule active

    1 trial
  4. Bisphosphocin Nu-3

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Infections

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Lakewood-Amedex Biotherapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.